ALT-801

Phase 2Small molecule

Altimmune

ALT-801 is one of 232 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

231

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Metastatic MelanomaActive, not recruiting

Bladder CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

ObesityActive, not recruiting

Non-Alcoholic Fatty Liver DiseasePhase 1

Active, not recruiting

Type 2 Diabetes MellitusPhase 1

Active, not recruiting

Metastatic MelanomaPhase 1/Phase 2

Active, not recruiting

Bladder CancerPhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

ObesityPhase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

ALT-801

Altimmune

Phase 2

1 2

Prolia

Amgen

Preclinical

5 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 4

Adriamycin

GGynecologic Oncology Group

Preclinical

9 5

Nolvadex

AstraZeneca

Preclinical

1 6

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 7

Intron a

Systemic Therapy

1 9

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

2 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overweight2 trials

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

Completed· Altimmune logo

Altimmune·Phase 1·NCT04561245·100 enrolled

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Completed· Altimmune logo

Altimmune·Phase 1·NCT05292911·64 enrolled

Metastatic Urothelial Cancer1 trial

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Completed·AAltor BioScience·Phase 1/2·NCT01326871·68 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Completed· Altimmune logo

Altimmune·Phase 1·NCT05006885·95 enrolled

Type 2 Diabetes Mellitus1 trial

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Completed· Altimmune logo

Altimmune·Phase 1·NCT05134662·55 enrolled

Acute Myeloid Leukemia1 trial

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Withdrawn·AAltor BioScience·Phase 1·NCT01478074

5 more indications

Obesity1 trial

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Completed· Altimmune logo

Altimmune·Phase 2·NCT05295875·391 enrolled

Multiple Myeloma1 trial

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Terminated·AAltor BioScience·Phase 1/2·NCT01670994·6 enrolled

Metastatic Melanoma1 trial

QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

Completed·AAltor BioScience·Phase 1/2·NCT01029873·25 enrolled

Bladder Cancer1 trial

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Terminated·AAltor BioScience·Phase 1/2·NCT01625260·12 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Completed·AAltor BioScience·Phase 1·NCT00496860·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for ALT-801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALT-801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALT-801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Altimmune company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Altimmune

ALT-801

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overweight2 trials

Metastatic Urothelial Cancer1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Type 2 Diabetes Mellitus1 trial

Acute Myeloid Leukemia1 trial

Obesity1 trial

Multiple Myeloma1 trial

Metastatic Melanoma1 trial

Bladder Cancer1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News